Precigen sees Q1 revenue exceeding $18M, consensus $20.8M
“In the short time since early and full approval, the standard-of-care first-line treatment is seeing tremendous progress,” said Precigen’s (PGEN) President and CEO, Helen Sabzevari, during a conference call to discuss fourth quarter results. “This substantial advancement constitutes a pivotal…












